Breaking News, Financial News

Financial Report: AMRI

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI

4Q Revenues: $47.2 million (+1%)

4Q Loss: $844,000 (loss of $764,000 in 4Q2006)

FY Revenues: $192.5 million (+7%)

FY Earnings: $8.9 million (earnings were $2.2 million FY2006)

Comments: Total contract and milestone revenue for the quarter was $41.1 million (+2%) and for the year was $165.5 million (+8%). Milestone revenue for the year was $2.1 million, which includes $1.5 million resulting from the company’s collaborative research agreement with Bristol-Myers Squibb. Development/small scale manufacturing revenue was $11.4 million (+22%) in the quarter and $45.4 million (+26%) for the year. Discovery services revenue was $11.5 million (-6%) in the quarter and $41.6 million (+5%) for the year. Large scale manufacturing revenue for the quarter was $17.7 million (-6%) and for the year was $76.3 million (-1%). Recurring royalties from Allegra in quarter were $6.1 million (-4%) and for the year were flat at $27.1 million. FY results include large scale manufacturing restructuring charges of $177,000.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters